Additional Information

Description

Venlafaxine ER 37.5 mg capsules are an extended-release formulation of venlafaxine hydrochloride, a serotonin-norepinephrine reuptake inhibitor (SNRI). This medication is commonly prescribed for the treatment of major depressive disorder, generalized anxiety disorder, and certain types of panic disorders. The extended-release formulation allows for once-daily dosing, improving patient adherence to therapy.

The 37.5 mg strength of venlafaxine is often used as an initial dose or for patients who require a lower dose for managing side effects. As a SNRI, venlafaxine affects both serotonin and norepinephrine pathways, which may make it more effective for patients who do not respond well to selective serotonin reuptake inhibitors (SSRIs).

Common side effects include nausea, dizziness, dry mouth, and insomnia. While most side effects are mild and transient, some patients may experience more severe reactions such as increased blood pressure or suicidal thoughts, particularly in the initial stages of treatment. Monitoring by healthcare professionals is recommended, especially in the early phases of therapy.